Eugenio Marco
Overview
Explore the profile of Eugenio Marco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janoudi T, Jagdale M, Wu M, Gorlla S, Zhang P, Shao Y, et al.
Blood Adv
. 2024 Dec;
9(4):808-813.
PMID: 39637306
No abstract available.
2.
Allen A, Khan S, Margulies C, Viswanathan R, Lele S, Blaha L, et al.
Nat Biotechnol
. 2023 May;
42(3):458-469.
PMID: 37127662
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this study, we used a CRISPR nuclease that targets a site within an exon of an essential gene...
3.
Fennell T, Zhang D, Isik M, Wang T, Gotta G, Wilson C, et al.
CRISPR J
. 2021 Apr;
4(2):264-274.
PMID: 33876962
We describe CALITAS, a CRISPR-Cas-aware aligner and integrated off-target search algorithm. CALITAS uses a modified and CRISPR-tuned version of the Needleman-Wunsch algorithm. It supports an unlimited number of mismatches and...
4.
Perry N, Wasko K, Cheng J, Tabbaa D, Marco E, Giannoukos G, et al.
J Immunol
. 2020 Dec;
206(2):446-451.
PMID: 33277386
Human regulatory T cells (Tregs) have been implicated in cancer immunotherapy and are also an emerging cellular therapeutic for the treatment of multiple indications. Although Treg stability during ex vivo...
5.
Bothmer A, Gareau K, Abdulkerim H, Buquicchio F, Cohen L, Viswanathan R, et al.
CRISPR J
. 2020 Jun;
3(3):177-187.
PMID: 32584143
Multiplexed genome editing with DNA endonucleases has broad application, including for cellular therapies, but chromosomal translocations, natural byproducts of inducing simultaneous genomic breaks, have not been explored in detail. Here...
6.
Debruyne D, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, et al.
Nature
. 2019 Aug;
572(7771):676-680.
PMID: 31391581
The CCCTC-binding factor (CTCF), which anchors DNA loops that organize the genome into structural domains, has a central role in gene control by facilitating or constraining interactions between genes and...
7.
Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G, et al.
Nat Med
. 2019 Jan;
25(2):229-233.
PMID: 30664785
Leber congenital amaurosis type 10 is a severe retinal dystrophy caused by mutations in the CEP290 gene. We developed EDIT-101, a candidate genome-editing therapeutic, to remove the aberrant splice donor...
8.
Shen S, Sanchez M, Blomenkamp K, Corcoran E, Marco E, Yudkoff C, et al.
Hum Gene Ther
. 2018 Apr;
29(8):861-873.
PMID: 29641323
Alpha-1 antitrypsin deficiency (AATD) is a hereditary liver disease caused by mutations in the SERPINA1 serine protease inhibitor gene. Most severe patients are homozygous for PiZ alleles (PiZZ; amino acid...
9.
Wilson C, Fennell T, Bothmer A, Maeder M, Reyon D, Cotta-Ramusino C, et al.
Nat Methods
. 2018 Mar;
15(4):236-237.
PMID: 29600989
No abstract available.
10.
Giannoukos G, Ciulla D, Marco E, Abdulkerim H, Barrera L, Bothmer A, et al.
BMC Genomics
. 2018 Mar;
19(1):212.
PMID: 29562890
Background: Understanding the diversity of repair outcomes after introducing a genomic cut is essential for realizing the therapeutic potential of genomic editing technologies. Targeted PCR amplification combined with Next Generation...